<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092857</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00005583</org_study_id>
    <secondary_id>230831</secondary_id>
    <nct_id>NCT02092857</nct_id>
  </id_info>
  <brief_title>Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants</brief_title>
  <official_title>Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <brief_summary>
    <textblock>
      The immune system of newborn infants is immature with low activity of both innate and
      acquired immune reactions. Early nutrition has an impact on early immune responses. Dietary
      fatty acids are one nutritional factor noted to play a role in immune function. The omega-6
      long-chain polyunsaturated fatty acid, ARA (Arachidonic acid) and the omega-3 fatty acid, DHA
      (docosahexaenoic acid) are found naturally in breastmilk and some infant formulas. The
      balance or relative amounts of ARA and DHA have been associated with immune response. Some
      commercial infant formula contains both ARA and DHA. However, the optimal balance of ARA and
      DHA has not been determined with respect to immune function. This study will assess two
      levels of ARA and the impact on immune response in healthy, term infants and whether genes
      that influence essential fatty acid metabolism alter the nutritional requirement of infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Antigen-presenting B Cells</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Focus: Nutritional Requirements for Infants</condition>
  <arm_group>
    <arm_group_label>34 mg/100 kcal arachidonic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg/100 kcal arachidonic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant formula without arachidonic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arachidonic acid (25 mg/100 kcal )</intervention_name>
    <arm_group_label>25 mg/100 kcal arachidonic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arachidonic acid (34 mg/100 kcal)</intervention_name>
    <arm_group_label>34 mg/100 kcal arachidonic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).</description>
    <arm_group_label>Infant formula without arachidonic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  healthy term infants

          -  birth weight, length and head circumference between the 5th and 95th percentile for
             gestational age (according to the National Center for Health Statistics growth charts)

          -  receiving &gt;80% for their intake by mouth from commercial infant formula

          -  low-risk for allergy based on a negative family history.

        Exclusion criteria:

          -  corticosteroid use

          -  red cell or plasma transfusions

          -  IV lipid emulsions prior to study entry

          -  major congenital malformations

          -  systemic or congenital infection

          -  significant neonatal morbidity

          -  maternal autoimmune disorders

          -  acute illness precluding oral feedings or conditions requiring feedings other than
             standard formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael T Clandinin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <results_first_submitted>March 24, 2014</results_first_submitted>
  <results_first_submitted_qc>March 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nutrient</keyword>
  <keyword>nutrition</keyword>
  <keyword>arachidonic acid</keyword>
  <keyword>essential fatty acids</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>34 mg/100 kcal Arachidonic Acid</title>
          <description>10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid</description>
        </group>
        <group group_id="P2">
          <title>25 mg/100 kcal Arachidonic Acid</title>
          <description>10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid</description>
        </group>
        <group group_id="P3">
          <title>Infant Formula Without Arachidonic Acid</title>
          <description>10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>34 mg/100 kcal Arachidonic Acid</title>
          <description>10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid</description>
        </group>
        <group group_id="B2">
          <title>25 mg/100 kcal Arachidonic Acid</title>
          <description>10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid</description>
        </group>
        <group group_id="B3">
          <title>Infant Formula Without Arachidonic Acid</title>
          <description>10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.8" spread="3.8"/>
                    <measurement group_id="B2" value="16.5" spread="3.8"/>
                    <measurement group_id="B3" value="17.8" spread="4.4"/>
                    <measurement group_id="B4" value="17" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Antigen-presenting B Cells</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>34 mg/100 kcal Arachidonic Acid</title>
            <description>10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid</description>
          </group>
          <group group_id="O2">
            <title>25 mg/100 kcal Arachidonic Acid</title>
            <description>10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid</description>
          </group>
          <group group_id="O3">
            <title>Infant Formula Without Arachidonic Acid</title>
            <description>10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Antigen-presenting B Cells</title>
          <units>percentage of CD20+ B cells</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="22.8"/>
                    <measurement group_id="O3" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>34 mg/100 kcal Arachidonic Acid</title>
          <description>10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid</description>
        </group>
        <group group_id="E2">
          <title>25 mg/100 kcal Arachidonic Acid</title>
          <description>10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid</description>
        </group>
        <group group_id="E3">
          <title>Infant Formula Without Arachidonic Acid</title>
          <description>10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sudden unexpected infant death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>swallowing disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroesophageal reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>cow's milk intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>inguinal hernia - male</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tom Clandinin</name_or_title>
      <organization>University of Alberta</organization>
      <phone>7804925188</phone>
      <email>tclandin@ualberta.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

